Emtricitabine News and Research

RSS
Emtricitabine, also known as Emtriva or FTC, is a type of medicine called a nucleoside reverse transcriptase inhibitor (NRTI). NRTIs block reverse transcriptase, a protein that HIV needs to make more copies of itself. Emtricitabine in capsule form was approved by the FDA on July 2, 2003, for use with other antiretroviral agents in the treatment of HIV infection in adults. Emtricitabine oral solution was approved by the FDA on September 28, 2005, and is now approved for use with other anti-HIV drugs in the treatment of HIV-1 infection in patients older than 3 months of age. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.
Mylan licenses rights to produce and market generic versions of Gilead HIV/AIDS therapies

Mylan licenses rights to produce and market generic versions of Gilead HIV/AIDS therapies

Gilead Sciences second quarter total revenues increase 13% to $2.41 billion

Gilead Sciences second quarter total revenues increase 13% to $2.41 billion

Dapivirine Phase III trial now underway in Africa to treat HIV in women

Dapivirine Phase III trial now underway in Africa to treat HIV in women

All adult patients with HIV should be offered ART: International Antiviral Society-USA panel

All adult patients with HIV should be offered ART: International Antiviral Society-USA panel

Clinical trial to evaluate maraviroc-based PrEP regimens for HIV prevention

Clinical trial to evaluate maraviroc-based PrEP regimens for HIV prevention

Truvada gains FDA approval as HIV preventive

Truvada gains FDA approval as HIV preventive

U.S. FDA approves Gilead’s Truvada to minimize risk of sexually-acquired HIV infection

U.S. FDA approves Gilead’s Truvada to minimize risk of sexually-acquired HIV infection

Gilead receives FDA approval for Truvada to reduce risk of sexually acquired HIV-1 infection

Gilead receives FDA approval for Truvada to reduce risk of sexually acquired HIV-1 infection

Once-daily single-tablet HIV therapy developed

Once-daily single-tablet HIV therapy developed

Dolutegravir-based regimen demonstrates superiority over Atripla in treatment-naive adults with HIV-1

Dolutegravir-based regimen demonstrates superiority over Atripla in treatment-naive adults with HIV-1

HIV infection risk reduced by same drugs that treat HIV

HIV infection risk reduced by same drugs that treat HIV

Once-daily pill for HIV is a safe and effective alternative to traditional antiretroviral regimens

Once-daily pill for HIV is a safe and effective alternative to traditional antiretroviral regimens

Gilead submits cobicistat NDA with FDA for treatment of HIV

Gilead submits cobicistat NDA with FDA for treatment of HIV

Gilead submits elvitegravir NDA with FDA for treatment of HIV-1 infection

Gilead submits elvitegravir NDA with FDA for treatment of HIV-1 infection

Gilead's elvitegravir MAA for HIV-1 infection receives EMA validation

Gilead's elvitegravir MAA for HIV-1 infection receives EMA validation

Pre-exposure preventive treatment may be effective against suspected HIV

Pre-exposure preventive treatment may be effective against suspected HIV

FDA ADAC recommends approval of Quad for HIV-1 infection

FDA ADAC recommends approval of Quad for HIV-1 infection

FDA ADAC recommends approval of Gilead’s Truvada for HIV

FDA ADAC recommends approval of Gilead’s Truvada for HIV

Truvada deemed safe & effective in HIV infection risk reduction

Truvada deemed safe & effective in HIV infection risk reduction

AIDS, health groups submit comments to FDA prior to agency's review of PrEP

AIDS, health groups submit comments to FDA prior to agency's review of PrEP